Skip to main content

Medincell

Medincell SA is a French biopharmaceutical company developing long-acting injectable prescription drugs utilizing its proprietary BEPO technology platform. The company formulates polymer-based injectable therapies for CNS disorders, pain management, and oncology, including Uzedy for schizophrenia commercialized with Teva. Revenue is primarily generated through research collaboration upfront payments, clinical development milestone fees, and commercial sales royalties from pharmaceutical partners. Core end markets encompass psychiatry clinics, hospital neurology departments, pain treatment centers, and prescription patients in North America and Europe. Medincell holds an innovative pioneer position in the global biopharmaceutical sector for long-acting injectable drug delivery platforms. The company is headquartered in Jacou, France, and its ordinary shares trade on Euronext Paris.

2 of the funds FundTelligence covers report a position in Medincell.

Legal name
MEDINCELL SA
Sector
Health Care
Country
France
Funds holding it
2

Funds holding Medincell

Loading...